Skip to main content

BIOS Fund I, LP's Form 4 filing

Lantern Pharma Inc. (LTRN) · filed Dec 1, 2023

Accession no.
0001104659-23-122540
Filed
Dec 1, 2023, 6:01 AM ET
Trade date
Nov 29, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $500.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
BIOS Fund I, LPCIK 000169731610% Owner
BIOS Fund I QP, LPCIK 000170029710% Owner
BIOS Fund II, LPCIK 000171457610% Owner
BIOS Fund II QP, LPCIK 000171686910% Owner
BIOS Fund II NT, LPCIK 000172885110% Owner
Fletcher Aaron G.L.CIK 000178949010% Owner
Bios Equity Partners II, LPCIK 000181331310% Owner
Bios Equity Partners, LPCIK 000181331410% Owner
BIOS Advisors GP, LLCCIK 000181384410% Owner
BIOS Capital Management, LPCIK 000181384510% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 29, 2023Common StockSSaleDisposed−53,640$3.44−$184,521.6217,553IndirectDuplicate filing
Nov 29, 2023Common StockSSaleDisposed−91,708$3.44−$315,475.52371,950IndirectDuplicate filing

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)